We are live on ! Find out more
ELVN icon

Enliven Therapeutics
ELVN

124 hedge funds and large institutions have $1.19B invested in Enliven Therapeutics in 2025 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 57 increasing their positions, 23 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

148% more repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 23

21% more capital invested

Capital invested by funds: $984M → $1.19B (+$208M)

20% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 20

19.31% more ownership

Funds ownership: 101.81% → 121.12% (+19%)

2% more funds holding

Funds holding: 121 → 124 (+3)

0% more funds holding in top 10

Funds holding in top 10: 7 → 7 (0)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $14K

Holders
124
Holders Change
+3
Holders Change %
+2.48%
% of All Funds
1.63%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
24
Increased
57
Reduced
23
Closed
20
Calls
–
Puts
$14K
Net Calls
-$14K
Net Calls Change
+$3K

Top Buyers

Rank Fund Capital Flow
1
Capital Research Global Investors
Capital Research Global Investors
California
+$24.9M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$23M
3
NHAS
Novo Holdings A/S
Denmark
+$20.5M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$18M
5
PCH
Polar Capital Holdings
United Kingdom
+$13M

Top Sellers

Rank Fund Capital Flow
1
BCM
Boxer Capital Management
California
-$13.2M
2
5VM
5AM Venture Management
California
-$10.4M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$6.7M
4
IC
Ikarian Capital
Texas
-$5.7M
5
ACP
Acuta Capital Partners
California
-$5.22M
Name Holding Trade Value Shares
Change 		Change in
Stake
Franklin Resources
26
Franklin Resources
California
$8.63M +$7.76M +410,034 +2,029%
CS
27
Candriam SCA
Luxembourg
$8.36M +$7.89M +416,650 New
AAA
28
Affinity Asset Advisors
New York
$8.02M +$7.57M +400,000 New
LGM
29
Logos Global Management
California
$7.02M +$2.08M +110,000 +46%
Marshall Wace
30
Marshall Wace
United Kingdom
$6.69M +$6.1M +322,173 +2,887%
Northern Trust
31
Northern Trust
Illinois
$6.51M -$265K -14,022 -4%
Millennium Management
32
Millennium Management
New York
$6.39M +$3.51M +185,562 +140%
Charles Schwab
33
Charles Schwab
California
$6.13M +$873K +46,123 +18%
ABG
34
Ally Bridge Group
New York
$5.64M +$2.11M +111,620 +66%
Morgan Stanley
35
Morgan Stanley
New York
$5.11M +$3.29M +173,533 +213%
VPC
36
Vestal Point Capital
New York
$5.01M +$4.73M +250,000 New
PSC
37
Patient Square Capital
California
$4.93M -$151K -8,000 -3%
CAM
38
Cormorant Asset Management
Massachusetts
$4.01M -$947K -50,000 -20%
Goldman Sachs
39
Goldman Sachs
New York
$3.8M -$421K -22,247 -11%
HS
40
HighVista Strategies
Massachusetts
$2.84M +$550K +29,057 +26%
UBS Group
41
UBS Group
Switzerland
$2.77M +$1.28M +67,844 +96%
SFM
42
Sphera Funds Management
Israel
$2.58M +$318K +16,772 +15%
BBA
43
Baker Bros. Advisors
New York
$2.3M – – –
Bank of New York Mellon
44
Bank of New York Mellon
New York
$1.97M +$86.4K +4,562 +5%
Adage Capital Partners
45
Adage Capital Partners
Massachusetts
$1.93M -$6.7M -354,000 -79%
Wellington Management Group
46
Wellington Management Group
Massachusetts
$1.89M +$176K +9,312 +11%
N
47
Nuveen
North Carolina
$1.8M -$272K -14,387 -14%
UBS AM
48
UBS AM
Illinois
$1.67M +$893K +47,156 +131%
Barclays
49
Barclays
United Kingdom
$1.46M +$425K +22,427 +45%
Royal Bank of Canada
50
Royal Bank of Canada
Ontario, Canada
$1.36M +$1.19M +62,688 +1,211%
1
2
3 4 5

ELVN Hedge Fund Activity: Q2 2025 in Review

124 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Enliven Therapeutics (ELVN) for Q2 2025, worth a combined $1.19B — up 21% from $984M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new ELVN positions and 20 closed out — a net gain of 4 holders — while 57 added to existing stakes and 23 trimmed.

The largest buyer was Capital Research Global Investors, opening a new position worth an estimated $24.9M. The largest seller was Boxer Capital Management, exiting entirely with an estimated $13.2M sold.

  • 124 institutional investors held Enliven Therapeutics (ELVN) as of Q2 2025, up from 121 in Q1 2025.
  • Funds reported $1.19B of Enliven Therapeutics stock for Q2 2025, up 21% quarter-over-quarter.
  • 24 funds opened new Enliven Therapeutics positions in Q2 2025 and 20 closed out, a net change of +4 holders.
  • The largest Enliven Therapeutics buyer in Q2 2025 was Capital Research Global Investors, an estimated $24.9M added.
  • The largest Enliven Therapeutics seller in Q2 2025 was Boxer Capital Management, an estimated $13.2M sold.

Based on aggregated 13F filings for Q2 2025.